Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Peak crossover: bezuclastinib and sunitinib after progression on sunitinib in GIST

Robin Jones, MBBS, MRCP, MD, Institute of Cancer Research, London, UK, describes crossover outcomes from the Phase III Peak (NCT05208047) trial, in which patients with advanced gastrointestinal stromal tumor (GIST) who progressed on sunitinib monotherapy received bezuclastinib plus sunitinib. The combination, which targets the full spectrum of primary and secondary KIT mutations, achieved meaningful responses and disease control after crossover, including among patients who had not responded to sunitinib. Safety was consistent with the randomized portion. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yes, so this morning I discussed and presented the results of the crossover analysis of the peak trial in advanced GIST. And the trial essentially randomized patients that had received prior therapy with imatinib to either receive bosutinib plus sunitinib or sunitinib alone. The primary analysis, the pivotal analysis from the trial were presented at ASCO earlier this year by Dr...

Yes, so this morning I discussed and presented the results of the crossover analysis of the peak trial in advanced GIST. And the trial essentially randomized patients that had received prior therapy with imatinib to either receive bosutinib plus sunitinib or sunitinib alone. The primary analysis, the pivotal analysis from the trial were presented at ASCO earlier this year by Dr. Wagner and the trial met the primary endpoint showing a significant benefit for the combination of bosutinib and sunitinib compared to sunitinib alone in terms of median progression-free survival. The analysis presented at ESMO today essentially looked at the outcome and safety of using the combination in patients that had experienced disease progression on sunitinib alone within the trial. So patients on sunitinib with disease progression were allowed to receive the combination therapy and the trial showed that the use of the combination schedule following sunitinib alone was beneficial both in terms of progression-free survival and response rate but was also comparable in terms of the safety profile to the pivotal portion of the trial.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.